Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for XENE

Stock Name	Xenon Pharmaceuticals Inc
Ticker	XENE(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	CA98420N1050

Show aggregate XENE holdings

News associated with XENE

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average volume of 165 put options. Institutional Trading of Xenon Pharmaceuticals Institutional investors have recently modified their holdings […] - 2025-09-18 04:48:00
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 4,063 put options on the company. Thisrepresentsanincreaseofapproximately2,362% compared to the typical volume of 165 put options. Analyst Ratings Changes A number of analysts have weighed in on the stock. Wall Street Zen downgraded […] - 2025-08-22 02:22:44
Royal Bank Of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target decreased by analysts at Royal Bank Of Canada from $57.00 to $55.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 46.00% […] - 2025-08-14 02:13:05
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wedbush Analyst Says: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target upped by stock analysts at Wedbush from $42.00 to $43.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 14.15% from […] - 2025-08-14 02:13:01
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade: Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) shares gapped up before the market opened on Tuesday after Wedbush raised their price target on the stock from $42.00 to $43.00. The stock had previously closed at $34.11, but opened at $36.00. Wedbush currently has an outperform rating on the stock. Xenon Pharmaceuticals shares last traded […] - 2025-08-13 02:36:44
11,949 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Y Intercept Hong Kong Ltd: Y Intercept Hong Kong Ltd bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,949 shares of the biopharmaceutical company’s stock, valued at approximately $401,000. Other large investors […] - 2025-07-29 05:16:54
Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average daily volume of 165 put options. Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock. […] - 2025-07-24 04:56:56
New York State Common Retirement Fund Buys 9,851 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE): New York State Common Retirement Fund lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,372 shares of the biopharmaceutical company’s stock after acquiring an additional 9,851 […] - 2025-07-22 07:10:51
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Hedge Funds Weigh In On Xenon Pharmaceuticals Several large investors have recently modified their holdings of […] - 2025-06-26 03:00:54
Comparing Xenon Pharmaceuticals (NASDAQ:XENE) & Inhibitor Therapeutics (OTCMKTS:INTI): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider & Institutional Ownership 95.4% of Xenon Pharmaceuticals […] - 2025-06-04 03:06:45
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages: Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have earned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage […] - 2025-05-26 04:40:52
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday. Other equities research analysts have also issued reports about the stock. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note […] - 2025-05-21 05:12:51
D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE): D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company’s stock after selling 117,919 shares during the quarter. D. […] - 2025-05-19 05:12:55
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $47.00 Price Target at Wells Fargo & Company: Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its target price cut by Wells Fargo & Company from $50.00 to $47.00 in a research report report published on Tuesday, Marketbeat.com reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts also recently issued reports on the company. William Blair reaffirmed […] - 2025-05-16 03:05:00
Needham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00: Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target trimmed by Needham & Company LLC from $60.00 to $55.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on XENE. The Goldman Sachs […] - 2025-05-16 03:04:59
Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Chardan Capital reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $55.00 price objective on the biopharmaceutical company’s stock. Several other research firms also recently commented on XENE. Royal Bank of Canada reiterated an “outperform” rating on shares of […] - 2025-05-16 03:04:56
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analysts Set New Price Targets Several research analysts recently issued reports […] - 2025-05-15 04:31:06
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target reduced by equities research analysts at Royal Bank of Canada from $58.00 to $55.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target […] - 2025-05-15 02:48:49
HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $53.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 78.21% from the stock’s previous close. Other research analysts […] - 2025-05-15 02:48:48
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to “Hold”: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday. A number of other equities research analysts have also recently commented on XENE. Royal Bank of Canada cut their target price on Xenon Pharmaceuticals from $58.00 to […] - 2025-05-15 02:16:49
Raymond James Financial Inc. Invests $797,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 20,331 shares of the biopharmaceutical company’s stock, valued at approximately $797,000. A number of […] - 2025-05-07 04:38:48
William Blair Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE): Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Monday,RTT News reports. XENE has been the topic of several other reports. The Goldman Sachs Group dropped their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set […] - 2025-05-07 02:22:49
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to “Sell” at StockNews.com: StockNews.com downgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) from a hold rating to a sell rating in a report released on Friday morning. XENE has been the topic of several other reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a […] - 2025-05-05 02:28:52
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance XENE opened at $38.20 on Thursday. The […] - 2025-05-01 04:46:54
Guggenheim Capital LLC Decreases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Guggenheim Capital LLC lowered its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 41.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,177 shares of the biopharmaceutical company’s stock after selling 4,452 shares during the quarter. Guggenheim Capital LLC’s holdings in […] - 2025-04-29 05:30:55
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from Analysts: Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […] - 2025-04-29 03:10:55
Invesco Ltd. Cuts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Invesco Ltd. cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,554 shares of the biopharmaceutical company’s stock after selling 6,268 shares during the quarter. […] - 2025-04-24 05:00:53
Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE): Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Wall Street Analyst Weigh In A number of analysts have commented on the […] - 2025-04-17 04:41:09
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to Sell at StockNews.com: Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday. Several other equities research analysts have also recently commented on XENE. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, […] - 2025-04-16 03:10:56
Trexquant Investment LP Has $447,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Trexquant Investment LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,397 shares of the biopharmaceutical company’s stock after selling 5,510 shares during the period. Trexquant […] - 2025-04-13 05:31:04

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc XENE holdings

Date	Number of XENE Shares Held	Base Market Value of XENE Shares	Local Market Value of XENE Shares	Change in XENE Shares Held	Change in XENE Base Value	Current Price per XENE Share Held	Previous Price per XENE Share Held
2026-01-15 (Thursday)	78,692	USD 3,205,912	USD 3,205,912	12,116	USD 437,682	USD 40.74	USD 41.58
2026-01-14 (Wednesday)	66,576	USD 2,768,230	USD 2,768,230	233	USD 90,627	USD 41.58	USD 40.36
2026-01-13 (Tuesday)	66,343	USD 2,677,603	USD 2,677,603	0	USD -57,719	USD 40.36	USD 41.23
2026-01-12 (Monday)	66,343	USD 2,735,322	USD 2,735,322	0	USD -61,035	USD 41.23	USD 42.15
2026-01-09 (Friday)	66,343	USD 2,796,357	USD 2,796,357	0	USD 61,699	USD 42.15	USD 41.22
2026-01-08 (Thursday)	66,343	USD 2,734,658	USD 2,734,658	233	USD -49,895	USD 41.22	USD 42.12
2026-01-07 (Wednesday)	66,110	USD 2,784,553	USD 2,784,553	0	USD 74,043	USD 42.12	USD 41
2026-01-06 (Tuesday)	66,110	USD 2,710,510	USD 2,710,510	0	USD -52,227	USD 41	USD 41.79
2026-01-05 (Monday)	66,110	USD 2,762,737	USD 2,762,737	0	USD -178,497	USD 41.79	USD 44.49
2026-01-02 (Friday)	66,110	USD 2,941,234	USD 2,941,234	0	USD -21,816	USD 44.49	USD 44.82
2025-12-31 (Wednesday)	66,110	USD 2,963,050	USD 2,963,050	0	USD 46,277	USD 44.82	USD 44.12

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of XENE by Blackrock for IE00B3VWM098

Show aggregate share trades of XENE

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 12,116 40.740* 37.72
2026-01-14 BUY 233 41.580* 37.70
2026-01-08 BUY 233 41.220* 37.64
2025-12-23 SELL -233 46.080 44.465 44.627 USD -10,398 37.38 Loss of -1,690 on sale
2025-12-03 SELL -1,165 44.692 42.880 43.061 USD -50,166 36.94 Loss of -7,135 on sale
2025-12-02 BUY 466 44.110 42.355 42.530 USD 19,819 36.91
2025-11-25 SELL -699 44.210 42.405 42.585 USD -29,767 36.73 Loss of -4,092 on sale
2025-11-24 SELL -699 42.150 40.640 40.791 USD -28,513 36.71 Loss of -2,856 on sale
2025-11-17 SELL -2,563 41.580 40.305 40.433 USD -103,628 36.61 Loss of -9,807 on sale
2025-11-12 SELL -233 40.500 39.330 39.447 USD -9,191 36.55 Loss of -675 on sale
2025-11-06 SELL -233 39.406 37.680 37.853 USD -8,820 36.51 Loss of -313 on sale
2025-11-05 SELL -2,330 39.215 37.865 38.000 USD -88,540 36.50 Loss of -3,505 on sale
2025-11-04 SELL -466 40.450 37.625 37.908 USD -17,665 36.48 Loss of -664 on sale
2025-11-03 SELL -466 41.700 40.130 40.287 USD -18,774 36.46 Loss of -1,784 on sale
2025-10-28 BUY 699 42.530 42.740 42.719 USD 29,861 36.33
2025-10-24 SELL -233 40.760 41.690 41.597 USD -9,692 36.28 Loss of -1,240 on sale
2025-10-15 BUY 1,398 41.900 42.185 42.157 USD 58,935 36.04
2025-10-02 BUY 233 39.200 39.410 39.389 USD 9,178 36.00
2025-09-30 BUY 466 40.150 40.355 40.334 USD 18,796 35.96
2025-08-21 SELL -233 38.180 38.230 38.225 USD -8,906 35.91 Loss of -539 on sale
2025-07-31 BUY 699 30.540 31.300 31.224 USD 21,826 35.93
2025-07-28 SELL -233 30.970 31.050 31.042 USD -7,233 36.02 Profit of 1,161 on sale
2025-06-30 SELL -466 31.300 32.570 32.443 USD -15,118 36.49 Profit of 1,888 on sale
2025-06-25 SELL -233 31.760 32.370 32.309 USD -7,528 36.59 Profit of 996 on sale
2025-06-20 SELL -466 32.050 32.720 32.653 USD -15,216 36.69 Profit of 1,879 on sale
2025-05-23 BUY 233 29.750 30.610 30.524 USD 7,112 37.65
2025-05-19 SELL -233 30.950 31.160 31.139 USD -7,255 37.89 Profit of 1,572 on sale
2025-05-15 SELL -699 29.570 30.070 30.020 USD -20,984 38.03 Profit of 5,596 on sale
2025-05-12 SELL -233 35.850 36.960 36.849 USD -8,586 38.20 Profit of 314 on sale
2025-05-09 SELL -233 35.020 36.400 36.262 USD -8,449 38.22 Profit of 457 on sale
2025-04-30 SELL -233 38.200 38.630 38.587 USD -8,991 38.32 Loss of -63 on sale
2025-04-24 SELL -466 38.200 38.240 38.236 USD -17,818 38.33 Profit of 43 on sale
2025-04-17 SELL -233 35.110 35.410 35.380 USD -8,244 38.46 Profit of 718 on sale
2025-04-15 SELL -699 33.030 34.080 33.975 USD -23,749 38.57 Profit of 3,212 on sale
2025-04-14 SELL -699 33.440 33.720 33.692 USD -23,551 38.63 Profit of 3,449 on sale
2025-04-09 SELL -932 31.590 31.740 31.725 USD -29,568 38.88 Profit of 6,667 on sale
2025-04-07 SELL -1,631 30.630 31.520 31.431 USD -51,264 39.10 Profit of 12,504 on sale
2025-04-04 SELL -2,330 29.400 30.760 30.624 USD -71,354 39.21 Profit of 20,010 on sale
2025-03-31 BUY 233 33.550 33.795 33.770 USD 7,869 39.48
2025-03-19 SELL -466 34.940 35.370 35.327 USD -16,462 39.96 Profit of 2,161 on sale
2025-03-14 SELL -1,404 35.320 36.245 36.152 USD -50,758 40.16 Profit of 5,625 on sale
2025-03-13 SELL -468 35.180 36.220 36.116 USD -16,902 40.23 Profit of 1,925 on sale
2025-03-12 SELL -7,956 35.480 35.950 35.903 USD -285,644 40.30 Profit of 34,974 on sale
2025-03-07 SELL -468 36.500 38.080 37.922 USD -17,747 40.53 Profit of 1,221 on sale
2025-03-06 SELL -702 37.280 37.890 37.829 USD -26,556 40.58 Profit of 1,932 on sale
2025-03-03 SELL -234 35.790 37.830 37.626 USD -8,804 40.79 Profit of 740 on sale
2025-02-28 SELL -27,105 37.020 37.670 37.605 USD -1,019,283 40.85 Profit of 87,942 on sale
2025-02-26 SELL -303 39.100 40.000 39.910 USD -12,093 40.92 Profit of 307 on sale
2025-02-25 SELL -909 37.650 38.520 38.433 USD -34,936 40.98 Profit of 2,314 on sale
2025-02-18 BUY 1,510 39.150 39.330 39.312 USD 59,361 41.16
2025-02-13 BUY 302 39.260 39.840 39.782 USD 12,014 41.29
2025-02-12 BUY 302 39.500 39.520 39.518 USD 11,934 41.33
2025-02-11 BUY 906 38.390 39.594 39.474 USD 35,763 41.39
2025-02-06 BUY 2,718 39.600 40.500 40.410 USD 109,834 41.52
2025-01-27 BUY 302 40.110 41.240 41.127 USD 12,420 41.84
2024-12-30 BUY 1,510 38.530 39.000 38.953 USD 58,819 42.11
2024-12-06 BUY 1,208 42.720 42.770 42.765 USD 51,660 42.10
2024-12-05 BUY 302 41.410 42.780 42.643 USD 12,878 42.12
2024-12-04 BUY 4,375 42.340 43.000 42.934 USD 187,836 42.11
2024-11-29 BUY 1,465 42.630 43.495 43.408 USD 63,593 42.10
2024-11-27 BUY 1,172 43.150 43.405 43.379 USD 50,841 42.00
2024-11-26 BUY 293 42.450 42.745 42.715 USD 12,516 41.98
2024-11-25 BUY 17,521 41.680 42.690 42.589 USD 746,202 42.00
2024-11-21 BUY 1,195 39.800 41.000 40.880 USD 48,852 42.16
2024-11-20 BUY 717 39.340 39.500 39.484 USD 28,310 42.31
2024-11-18 BUY 2,868 38.310 40.040 39.867 USD 114,339 42.78
2024-11-12 BUY 1,912 43.390 44.500 44.389 USD 84,872 42.74
2024-11-08 BUY 1,195 45.000 46.000 45.900 USD 54,851 42.58
2024-11-07 BUY 3,585 45.740 45.820 45.812 USD 164,236 42.34
2024-11-06 BUY 478 44.940 45.020 45.012 USD 21,516 42.12
2024-10-31 BUY 238 41.110 42.340 42.217 USD 10,048 42.20
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	12,116			40.740*		37.72
2026-01-14	BUY	233			41.580*		37.70
2026-01-08	BUY	233			41.220*		37.64
2025-12-23	SELL	-233	46.080	44.465	44.627	USD -10,398	37.38 Loss of -1,690 on sale
2025-12-03	SELL	-1,165	44.692	42.880	43.061	USD -50,166	36.94 Loss of -7,135 on sale
2025-12-02	BUY	466	44.110	42.355	42.530	USD 19,819	36.91
2025-11-25	SELL	-699	44.210	42.405	42.585	USD -29,767	36.73 Loss of -4,092 on sale
2025-11-24	SELL	-699	42.150	40.640	40.791	USD -28,513	36.71 Loss of -2,856 on sale
2025-11-17	SELL	-2,563	41.580	40.305	40.433	USD -103,628	36.61 Loss of -9,807 on sale
2025-11-12	SELL	-233	40.500	39.330	39.447	USD -9,191	36.55 Loss of -675 on sale
2025-11-06	SELL	-233	39.406	37.680	37.853	USD -8,820	36.51 Loss of -313 on sale
2025-11-05	SELL	-2,330	39.215	37.865	38.000	USD -88,540	36.50 Loss of -3,505 on sale
2025-11-04	SELL	-466	40.450	37.625	37.908	USD -17,665	36.48 Loss of -664 on sale
2025-11-03	SELL	-466	41.700	40.130	40.287	USD -18,774	36.46 Loss of -1,784 on sale
2025-10-28	BUY	699	42.530	42.740	42.719	USD 29,861	36.33
2025-10-24	SELL	-233	40.760	41.690	41.597	USD -9,692	36.28 Loss of -1,240 on sale
2025-10-15	BUY	1,398	41.900	42.185	42.157	USD 58,935	36.04
2025-10-02	BUY	233	39.200	39.410	39.389	USD 9,178	36.00
2025-09-30	BUY	466	40.150	40.355	40.334	USD 18,796	35.96
2025-08-21	SELL	-233	38.180	38.230	38.225	USD -8,906	35.91 Loss of -539 on sale
2025-07-31	BUY	699	30.540	31.300	31.224	USD 21,826	35.93
2025-07-28	SELL	-233	30.970	31.050	31.042	USD -7,233	36.02 Profit of 1,161 on sale
2025-06-30	SELL	-466	31.300	32.570	32.443	USD -15,118	36.49 Profit of 1,888 on sale
2025-06-25	SELL	-233	31.760	32.370	32.309	USD -7,528	36.59 Profit of 996 on sale
2025-06-20	SELL	-466	32.050	32.720	32.653	USD -15,216	36.69 Profit of 1,879 on sale
2025-05-23	BUY	233	29.750	30.610	30.524	USD 7,112	37.65
2025-05-19	SELL	-233	30.950	31.160	31.139	USD -7,255	37.89 Profit of 1,572 on sale
2025-05-15	SELL	-699	29.570	30.070	30.020	USD -20,984	38.03 Profit of 5,596 on sale
2025-05-12	SELL	-233	35.850	36.960	36.849	USD -8,586	38.20 Profit of 314 on sale
2025-05-09	SELL	-233	35.020	36.400	36.262	USD -8,449	38.22 Profit of 457 on sale
2025-04-30	SELL	-233	38.200	38.630	38.587	USD -8,991	38.32 Loss of -63 on sale
2025-04-24	SELL	-466	38.200	38.240	38.236	USD -17,818	38.33 Profit of 43 on sale
2025-04-17	SELL	-233	35.110	35.410	35.380	USD -8,244	38.46 Profit of 718 on sale
2025-04-15	SELL	-699	33.030	34.080	33.975	USD -23,749	38.57 Profit of 3,212 on sale
2025-04-14	SELL	-699	33.440	33.720	33.692	USD -23,551	38.63 Profit of 3,449 on sale
2025-04-09	SELL	-932	31.590	31.740	31.725	USD -29,568	38.88 Profit of 6,667 on sale
2025-04-07	SELL	-1,631	30.630	31.520	31.431	USD -51,264	39.10 Profit of 12,504 on sale
2025-04-04	SELL	-2,330	29.400	30.760	30.624	USD -71,354	39.21 Profit of 20,010 on sale
2025-03-31	BUY	233	33.550	33.795	33.770	USD 7,869	39.48
2025-03-19	SELL	-466	34.940	35.370	35.327	USD -16,462	39.96 Profit of 2,161 on sale
2025-03-14	SELL	-1,404	35.320	36.245	36.152	USD -50,758	40.16 Profit of 5,625 on sale
2025-03-13	SELL	-468	35.180	36.220	36.116	USD -16,902	40.23 Profit of 1,925 on sale
2025-03-12	SELL	-7,956	35.480	35.950	35.903	USD -285,644	40.30 Profit of 34,974 on sale
2025-03-07	SELL	-468	36.500	38.080	37.922	USD -17,747	40.53 Profit of 1,221 on sale
2025-03-06	SELL	-702	37.280	37.890	37.829	USD -26,556	40.58 Profit of 1,932 on sale
2025-03-03	SELL	-234	35.790	37.830	37.626	USD -8,804	40.79 Profit of 740 on sale
2025-02-28	SELL	-27,105	37.020	37.670	37.605	USD -1,019,283	40.85 Profit of 87,942 on sale
2025-02-26	SELL	-303	39.100	40.000	39.910	USD -12,093	40.92 Profit of 307 on sale
2025-02-25	SELL	-909	37.650	38.520	38.433	USD -34,936	40.98 Profit of 2,314 on sale
2025-02-18	BUY	1,510	39.150	39.330	39.312	USD 59,361	41.16
2025-02-13	BUY	302	39.260	39.840	39.782	USD 12,014	41.29
2025-02-12	BUY	302	39.500	39.520	39.518	USD 11,934	41.33
2025-02-11	BUY	906	38.390	39.594	39.474	USD 35,763	41.39
2025-02-06	BUY	2,718	39.600	40.500	40.410	USD 109,834	41.52
2025-01-27	BUY	302	40.110	41.240	41.127	USD 12,420	41.84
2024-12-30	BUY	1,510	38.530	39.000	38.953	USD 58,819	42.11
2024-12-06	BUY	1,208	42.720	42.770	42.765	USD 51,660	42.10
2024-12-05	BUY	302	41.410	42.780	42.643	USD 12,878	42.12
2024-12-04	BUY	4,375	42.340	43.000	42.934	USD 187,836	42.11
2024-11-29	BUY	1,465	42.630	43.495	43.408	USD 63,593	42.10
2024-11-27	BUY	1,172	43.150	43.405	43.379	USD 50,841	42.00
2024-11-26	BUY	293	42.450	42.745	42.715	USD 12,516	41.98
2024-11-25	BUY	17,521	41.680	42.690	42.589	USD 746,202	42.00
2024-11-21	BUY	1,195	39.800	41.000	40.880	USD 48,852	42.16
2024-11-20	BUY	717	39.340	39.500	39.484	USD 28,310	42.31
2024-11-18	BUY	2,868	38.310	40.040	39.867	USD 114,339	42.78
2024-11-12	BUY	1,912	43.390	44.500	44.389	USD 84,872	42.74
2024-11-08	BUY	1,195	45.000	46.000	45.900	USD 54,851	42.58
2024-11-07	BUY	3,585	45.740	45.820	45.812	USD 164,236	42.34
2024-11-06	BUY	478	44.940	45.020	45.012	USD 21,516	42.12
2024-10-31	BUY	238	41.110	42.340	42.217	USD 10,048	42.20

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of XENE

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	94,121	0	116,537	80.8%
2025-09-18	166,160	0	196,562	84.5%
2025-09-17	153,610	0	353,729	43.4%
2025-09-16	127,586	0	236,754	53.9%
2025-09-15	95,792	14	178,183	53.8%
2025-09-12	70,043	0	198,178	35.3%
2025-09-11	96,068	0	181,331	53.0%
2025-09-10	122,078	0	189,803	64.3%
2025-09-09	90,865	0	283,996	32.0%
2025-09-08	232,027	100	301,530	76.9%
2025-09-05	156,900	0	238,492	65.8%
2025-09-04	166,307	0	271,514	61.3%
2025-09-03	157,066	0	271,074	57.9%
2025-09-02	81,739	0	248,041	33.0%
2025-08-29	152,207	0	232,164	65.6%
2025-08-28	61,706	0	157,013	39.3%
2025-08-27	83,791	0	140,984	59.4%
2025-08-26	138,841	12	233,008	59.6%
2025-08-25	90,644	0	153,535	59.0%
2025-08-22	241,402	0	680,379	35.5%
2025-08-21	240,881	0	412,449	58.4%
2025-08-20	121,216	0	174,820	69.3%
2025-08-19	140,464	0	214,610	65.5%
2025-08-18	180,294	0	305,703	59.0%
2025-08-15	160,339	2,610	215,321	74.5%
2025-08-14	238,992	0	350,208	68.2%
2025-08-13	372,443	0	746,027	49.9%
2025-08-12	467,887	0	696,577	67.2%
2025-08-11	270,332	55	374,372	72.2%
2025-08-08	242,928	90	362,883	66.9%
2025-08-07	167,847	368	222,326	75.5%
2025-08-06	192,634	0	261,533	73.7%
2025-08-05	641,973	50	1,267,219	50.7%
2025-08-04	456,814	0	843,073	54.2%
2025-08-01	190,981	5,139	229,705	83.1%
2025-07-31	195,002	781	223,443	87.3%
2025-07-30	154,824	900	252,506	61.3%
2025-07-29	243,814	1,587	303,064	80.4%
2025-07-28	320,579	0	650,128	49.3%
2025-07-25	214,658	100	341,862	62.8%
2025-07-24	138,436	0	204,720	67.6%
2025-07-23	119,232	0	205,068	58.1%
2025-07-22	103,454	0	214,734	48.2%
2025-07-21	212,989	0	246,308	86.5%
2025-07-18	176,030	0	205,045	85.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE